Bausch Health Companies Inc.

Trading Arrangements

On May 21, 2026, Aimee Lenar, President, US Pharma, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The trading arrangement, which is scheduled to expire on March 1, 2027, provides for the potential sale of: (i) up to 21,953 common shares of the Company held by Ms. Lenar and (ii) up to 73,441 common shares issuable to Ms. Lenar upon the vesting and settlement of restricted share units during the term of the arrangement. The number of shares sold under clause (ii) will be limited to 50% of the net common shares delivered to Ms. Lenar upon the vesting and settlement of up to 146,882 restricted share units, after giving effect to applicable tax withholding.

On May 28, 2026, Frank Lee, a member of the Board of Directors of the Company, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The trading arrangement, which is scheduled to expire on May 28, 2027, provides for the potential sale of up to 20,642 common shares of the Company issuable to Mr. Lee upon the vesting and settlement of restricted share units granted to him as part of his annual non-employee director equity award, including to fund estimated tax obligations arising from such award.